Erytech Pharma SA ADR (ERYP)

4.310
-0.290(-6.30%)
  • Volume:
    15,233
  • Bid/Ask:
    4.180/4.310
  • Day's Range:
    4.200 - 4.410

ERYP Overview

Prev. Close
4.6
Day's Range
4.2-4.41
Revenue
-
Open
4.41
52 wk Range
4.2-13.95
EPS
-
Volume
15,233
Market Cap
81.53M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
13,792
P/E Ratio
-
Beta
-
1-Year Change
-42.43%
Shares Outstanding
26,409,889
Next Earnings Date
Sep 20, 2021
What is your sentiment on Erytech Pharma SA ADR?
or
Vote to see community's results!

Erytech Pharma SA ADR News

Erytech Pharma SA ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsBuyNeutralStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell

Erytech Pharma SA ADR Company Profile

Erytech Pharma SA ADR Company Profile

Employees
206

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen’s University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.